EpimAb Biotherapeutics
Shanghai, China· Est.
Develops bispecific antibodies using its proprietary FIT-Ig platform for the treatment of cancer and autoimmune diseases.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
About
Develops bispecific antibodies using its proprietary FIT-Ig platform for the treatment of cancer and autoimmune diseases.
AntibodiesOncologyImmunology